bioAffinity Technologies Raises $3.2M in Public Offering
Event summary
- bioAffinity Technologies priced a $3.2M public offering of 4M shares at $0.80 per share, closing expected June 18, 2026.
- The offering includes common stock and pre-funded warrants exercisable for one share each.
- Proceeds will be used for general corporate purposes, deducting agent fees and expenses.
- CyPath® Lung, the company's noninvasive lung cancer detection test, demonstrated 92% sensitivity and 87% specificity in clinical trials.
The big picture
bioAffinity Technologies' $3.2M offering reflects the growing demand for noninvasive cancer detection tools. The funding comes as the biotech sector increasingly focuses on early-stage diagnostics, driven by advancements in AI and flow cytometry. The company's ability to scale CyPath® Lung will depend on its execution and regulatory environment.
What we're watching
- Funding Utilization
- How bioAffinity Technologies will allocate the $3.2M proceeds to advance CyPath® Lung and other initiatives.
- Market Adoption
- The pace at which CyPath® Lung gains traction among high-risk patients and healthcare providers.
- Regulatory Compliance
- Whether the company can navigate CLIA oversight and other regulatory hurdles for its LDT.
Related topics